Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.
Shanmugam V, Ramanathan RK, Lavender NA, Sinari S, Chadha M, Liang WS, Kurdoglu A, Izatt T, Christoforides A, Benson H, Phillips L, Baker A, Murray C, Hostetter G, Von Hoff DD, Craig DW, Carpten JD. Shanmugam V, et al. Among authors: von hoff dd. BMC Med Genomics. 2014 Jun 18;7:36. doi: 10.1186/1755-8794-7-36. BMC Med Genomics. 2014. PMID: 24943349 Free PMC article.
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.
Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H. Balagurunathan Y, et al. Among authors: von hoff dd. Mol Cancer Ther. 2008 Sep;7(9):3071-80. doi: 10.1158/1535-7163.MCT-08-0402. Epub 2008 Sep 2. Mol Cancer Ther. 2008. PMID: 18765825 Free PMC article.
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD. Warner SL, et al. Among authors: von hoff dd. Clin Cancer Res. 2009 Nov 1;15(21):6519-28. doi: 10.1158/1078-0432.CCR-09-0077. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861455 Free PMC article.
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD. Ramanathan RK, et al. Among authors: von hoff dd. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9. doi: 10.1007/s00280-010-1343-8. Epub 2010 May 12. Cancer Chemother Pharmacol. 2011. PMID: 20461382 Clinical Trial.
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Von Hoff DD, et al. J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921468
Advancing a clinically relevant perspective of the clonal nature of cancer.
Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, Von Hoff D, Barrett MT. Ruiz C, et al. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12054-9. doi: 10.1073/pnas.1104009108. Epub 2011 Jul 5. Proc Natl Acad Sci U S A. 2011. PMID: 21730190 Free PMC article.
773 results